Boryung Corporation Overview
Boryung is a mid-sized, prescription-led Korean pharmaceutical company that crossed KRW 1 trillion in annual revenue for the first time in FY2024 and ranks around eighth among Korean traditional pharma groups by sales. Its franchise rests on three pillars: (1) Kanarb (fimasartan), Korea's most commercially successful home-grown new drug and the base of a family of hypertension and dyslipidaemia combinations; (2) an oncology business built through "Legacy Brands Acquisition" (LBA) — buying and in-sourcing manufacture of off-patent originator brands such as Gemzar, Alimta and, since June 2026, the global Taxotere business acquired from Sanofi; and (3) a cytotoxic and oral-solid manufacturing hub at Yesan Campus that is now being monetised through global CDMO contracts. Under third-generation owner-CEO Jay Kim, the company is reorganising into a manufacturing/R&D/global parent with a separately incorporated commercial subsidiary, while also making long-dated bets on space life sciences through Axiom Space and its BRAX Space joint venture.
What the company does
Boryung manufactures, imports, licenses and sells finished pharmaceuticals, overwhelmingly to the Korean prescription (ETC) market. Its revenue derives from four broad activities:
-
Self-developed branded drugs — chiefly the Kanarb family (fimasartan mono and fixed-dose combinations), which represented about 15% of FY2024 revenue (KRW 150.9 billion, iNews24, 2025) and 15.9% of FY2025 revenue (HuffPost Korea, Aug 2026), plus incrementally modified drugs and first-to-file generics (e.g., Lenvanib, a lenvatinib generic approved February 2025).
-
Acquired originator ("LBA") brands — Gemzar (gemcitabine, Korean rights from Eli Lilly, 2020), Zyprexa (olanzapine, Korean rights from Lilly, 2021), Alimta (pemetrexed, Korean rights from Lilly, 2022) and Taxotere (docetaxel, global business in 19 countries/regions from Sanofi, closed May/June 2026). Boryung transfers manufacturing of these products in-house to Yesan, improving gross margin (Dealsite, 2025; Daily Pharm, 2025–2026).
-
In-licensed / co-promoted products ("merchandise") — e.g., Lilly's Trulicity distribution, HK inno.N's K-CAB co-promotion from 2024 (IBK Securities, Jan/Apr 2024), Organon's Atozet exclusive distribution from August 2026 (Daily Pharm headline, Aug 2026), and biosimilars. The 2023 Daily Pharm interview with then co-CEO Chang Doo-hyun put merchandise at about 40.6% of sales, low by Korean standards.
-
Contract manufacturing (CDMO) and exports — Alimta injectable supply to Lotus (Taiwan, contract Dec 2024, first shipment May 2026), Zyprexa tablets to Cheplapharm for up to 46 countries (contract Jul 2025, exports from Q4 2026), Alimta to Zuellig Pharma for seven Southeast Asian markets (contract Oct 2025, supply from 2027), and Taxotere global supply including a seven-year USD 277.1 million contract with China's Yifan Pharmaceutical (Sept 2026).
Consumer/OTC brands historically associated with Boryung — Gelfos (antacid) and Yonggaksan (cough/expectorant) — are manufactured by Boryung, while their OTC marketing and sales are conducted by Boryung Consumer Healthcare, a 100% subsidiary of the parent Boryung Holdings (not of the listed company) since 2018 (Daily Pharm, Apr 2020; Dealsite, Apr 2024). Gelfos holds roughly 30% of the Korean OTC antacid market (Daily Pharm, Jun 2026).
Business and revenue model
| Revenue type | Description | Share of revenue |
|---|---|---|
| Product sales — own manufactured goods | Kanarb family, in-sourced LBA brands, generics, OTC goods supplied to affiliate | ~59.4% of sales at 3Q22 (Daily Pharm, Feb 2023); later figure not publicly disclosed |
| Merchandise sales — purchased finished goods | In-licensed/co-promoted products (K-CAB, Trulicity, Atozet etc.) | ~40.6% (Daily Pharm, Feb 2023); later figure not publicly disclosed |
| Contract manufacturing / CDMO | Lotus, Cheplapharm, Zuellig; prior domestic contract manufacturing | Not separately disclosed; "Other (export, contract mfg.)" was KRW 75.1bn in FY2023 (IBK Securities) |
| Licensing / royalty | Kanarb out-licensing (Latin America, Russia, China, SE Asia) | Not publicly disclosed (small) |
| Subscription | — | 0% |
Company's own description
In recruitment and corporate materials, Boryung describes itself as a business that began as Boryung Pharmacy in 1957, entered drug manufacturing in 1963 and grew with Yonggaksan and Gelfos, launched Kanarb in 2011, adopted the LBA strategy in 2020, and passed KRW 1 trillion in sales in 2024, with an ambition to become Korea's leading pharmaceutical company (Remember career postings, 2025–2026). Its mission statement is to become a company indispensable to human health. Its English-language press materials since 2022 have described the group as a "healthcare investment company" (KED Global, Jan 2024; Axiom Space press release, Jan 2024).
Independent characterisation
Boryung is best understood as a Korean specialty-brand consolidator with captive manufacturing: rather than funding high-risk novel-drug discovery, it buys proven off-patent originator brands, in-sources their production to capture gross margin, and then reuses the resulting regulatory dossiers and EU-GMP capacity to sell manufacturing services and the brands themselves internationally. Kanarb provides a domestic cash engine but is now in post-patent erosion. The space-healthcare programme is a capital-allocation choice by the controlling family rather than an operating business — it has generated no reported revenue (Daily Pharm, Sept 2026).
Value-chain position: Formulation, manufacturing (finished dose; not API), regulatory ownership, marketing and distribution. Customers: hospitals (tertiary and secondary), clinics, pharmacies via wholesalers; global pharma partners (CDMO); national distributors abroad (Taxotere). End-markets: cardiovascular/metabolic (hypertension, dyslipidaemia, diabetes), oncology (cytotoxics, targeted generics, supportive care), CNS (Zyprexa ~75.7% of CNS sales in Q1 2026, Dealsite TV, Jun 2026), respiratory/anti-infectives (Mucomyst, Maxipime), gastroenterology.
Strategy
Stated strategy (themes from management communications)
-
Become an "indispensable" supplier of strategic essential medicines — secure in-house production capacity for drugs critical to national supply chains, then use that capacity to drive profit and global growth (Feb 2025 board statement; Nov 2024 rights-issue rationale).
-
LBA (Legacy Brands Acquisition) — acquire proven originator brands, internalise manufacturing, improve formulations (e.g., liquid Gemzar and Alimta), and now acquire global rather than Korea-only rights (Taxotere).
-
"Great Kanarb" — continuously launch new Kanarb-based combinations; target was KRW 200bn family sales by 2026 (Daily Pharm, Feb and Jul 2023). On disclosed run-rates (~KRW 150–160bn), this target appears unlikely to be met in FY2026.
-
Global CDMO for cytotoxics and oral solids — monetise Yesan's EU-GMP capacity (Lotus, Cheplapharm, Zuellig).
-
Commercial specialisation — BPS spin-off (2027) to in-license third-party blockbusters and use CSOs for non-core products; AI-enabled sales (Daily Pharm headline, Aug 2026).
-
Space life sciences ("Humans In Space") — positioned by the CEO as the company's second pillar alongside pharma (Daily Pharm, Mar 2025).
Initiatives in the last 24 months
| Date | Initiative | Detail |
|---|---|---|
| Nov 2024 | KRW 175bn equity raise | KRW 50bn facilities, KRW 50bn acquisitions of other companies, KRW 75bn working capital; fund plant expansion, essential-medicine supply, global CDMO, space |
| Dec 2024 – Oct 2025 | Three global CDMO contracts | Lotus, Cheplapharm, Zuellig |
| 2,025 | Partial outsourcing of sales to CSOs | Focus own reps on large brands (Daily Pharm, Sept 2026) |
| Sept 2025 – Jun 2026 | Taxotere global acquisition | First Korean acquisition of a big-pharma originator oncology business for global sale |
| May 2026 | Kanarb Jet launch | Triple combo with statin + ezetimibe |
| Jun 2026 | All-employee equity scheme | KRW 20bn treasury purchase |
| Sept 2026 | BPS spin-off | 2030 targets: +26 own products, +16 in-licensed, >10% domestic share |
| Sept 2026 | Yifan Taxotere China contract | USD 277.1m, 7 years |
| Ongoing | ESG | 2050 carbon-neutral roadmap, third-party GHG verification, NDC 2035 response |
Cost programmes with quantified targets: not publicly disclosed.
Medium-term targets / guidance
-
Earlier target of KRW 1 trillion revenue by 2026 (KED Global, Jul 2023) — achieved in FY2024.
-
2024 guidance reportedly KRW 1 trillion revenue and KRW 85bn operating profit (Daily Pharm headline, 2024) — revenue met, operating profit missed (KRW 70.5bn).
-
FY2026 formal guidance: not publicly disclosed in sources reviewed.
-
BPS 2030 targets as above.
Products & Services
Cardiovascular & metabolic (ETC)
| Product | Description | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Kanarb (fimasartan) 30/60/120 mg | ARB antihypertensive; indications: essential hypertension and reduction of proteinuria in hypertensive type 2 diabetic CKD | Cardiologists, GPs | Launched 2011 | Substance patent expired 2023; proteinuria-use patent runs to 2036 (Dealsite, Feb 2026). Price cut notified Jun 2025 (30 mg KRW 439→307; 60 mg 642→450; 120 mg 758→531), currently stayed pending appeal |
| Kanarb Plus | Fimasartan + hydrochlorothiazide | Same | — | Family member |
| Dukarb | Fimasartan + amlodipine | Same | — | Price-cut litigation also covers Dukarb (Daily Pharm, Feb 2026) |
| Dukarb Plus | Triple fixed-dose combination | Same | — | Family member |
| Tuvero | Fimasartan + rosuvastatin | Same | — | Family member |
| Dukaro | Fimasartan + amlodipine + rosuvastatin | Same | — | Family member (IBK, 2021) |
| Akarb | Fimasartan + atorvastatin | Same | — | Family member (IBK, 2021) |
| Kanarb Jet | Fimasartan + atorvastatin + ezetimibe | Hypertension with dyslipidaemia | Launched May 2026 | KRW 3.7bn initial stock delivered in Q2 2026; Daily Pharm headline reports a 42% share within a month (segment basis not specified) |
| Lacor | Kanarb-based combination | — | — | Marketed by Dongwha Pharm (Daily Pharm, 2021) |
| Diabetes portfolio | Generics/IMDs (unnamed) | Endocrinologists, GPs | 2023 onwards | Q1 2025 sales KRW 4.5bn, +65.9% YoY (Dealsite, Apr 2025) |
| Trulicity (dulaglutide) | GLP-1 RA, Lilly (distribution) | Diabetes | Imported | Supply shortages noted in 2024 (IBK) |
| Atozet | Ezetimibe/atorvastatin, Organon | Dyslipidaemia | Exclusive distribution from Aug 2026 | Daily Pharm headline, Aug 2026 |
Oncology (ETC — ONCO division)
| Product | Description | Launch / acquisition | Notes |
|---|---|---|---|
| Taxotere (docetaxel) | Originator cytotoxic taxane (breast, lung, prostate, gastric, head & neck cancers); WHO Essential Medicine | Global business in 19 countries/regions acquired from Sanofi; revenue from June 2026 | 2024 global sales EUR 70m (KRW 115.4bn) (Hankyung, Sept 2025); China is largest market; manufacturing to transfer to Yesan |
| Gemzar (gemcitabine) | Originator cytotoxic (pancreatic, lung, others) | Korean rights from Lilly May 2020 | Liquid formulation launched; in-house manufacture |
| Alimta (pemetrexed) | Originator antifolate (NSCLC, mesothelioma) | Korean rights from Lilly 2022 | In-house production; liquid formulation launched; CDMO supply to Lotus (2026) and Zuellig (from 2027) |
| Ditaxel (docetaxel generic) | Leading generic docetaxel in Korea | — | Must be divested within 6 months of 4 Jun 2026 (extendable 6 months) under KFTC remedy |
| Lenvanib (lenvatinib) | First generic of Lenvima (HCC, thyroid, RCC) | Approved Feb 2025; reimbursed May 2025 | Boryung invalidated/avoided all non-substance Lenvima patents |
| Cabozantinib generic (planned) | Generic of Cabometyx | Earliest launch moved to 2030 | Partial invalidation of unlisted patent, May 2026 |
| Palbociclib generic (planned) | Generic of Ibrance | Near-term | Daily Pharm, May 2026 |
| Belkin (bortezomib) | Generic for multiple myeloma | Yesan production from Dec 2020 | Daily Pharm, Jan 2021 |
| Oxaliplatin and other cytotoxic generics | Yesan-produced injectables | 2021 onwards | Daily Pharm, Jan 2021 |
| Xeloda (capecitabine), Genexol (paclitaxel), Megace, Campto | Imported/partner oncology brands historically marketed | Pre-2021 | IBK, 2021 |
| Zepzelca (lurbinectedin) | Small-cell lung cancer | Planned 2023 launch | Daily Pharm, Feb 2023 |
| Xbrik (denosumab biosimilar, Samsung Bioepis) | Bone metastasis | Launched in Korea | Secondary AI-aggregated news summary |
| Oncology biosimilars & supportive care | Various | 2022 onwards | Daily Pharm, Jul 2023 |
CNS, respiratory, anti-infective, GI (ETC)
| Product | Description | Notes |
|---|---|---|
| Zyprexa (olanzapine) | Atypical antipsychotic | Korean rights from Lilly 2021; in-house production completed 2024–2025; 75.7% of CNS sales in Q1 2026; supplied to Cheplapharm for up to 46 countries from Q4 2026 |
| Mucomyst | Bronchitis / mucolytic | Q1 2025 sales KRW 6.0bn, +5.5% YoY |
| Maxipime | Antibiotic (cefepime) | Q1 2025 sales KRW 3.7bn, +14.7% YoY |
| Stogar | Anti-ulcer | First product produced at Yesan (2020) |
| K-CAB (tegoprazan) | P-CAB for acid-related disease, HK inno.N | Co-promotion from 2024 |
OTC / consumer (manufactured by Boryung, marketed by affiliate Boryung Consumer Healthcare)
| Brand | Description | Notes |
|---|---|---|
| Gelfos M / Gelfos L | Liquid antacid (aluminium phosphate, magnesium hydroxide, simethicone); Gelfos L adds a digestive ingredient | ~30% share of Korean OTC antacid market; FY2024 brand sales KRW 18.5bn; 12-pack launched Jun 2026 |
| Yonggaksan / Yonggaksan Cool | Powder/granule cough and expectorant | Heritage brand produced since 1967 |
| Yonggaksu | Gargle / oral rinse | Brand extension |
Services
| Service | Description | Customers |
|---|---|---|
| Cytotoxic injectable CDMO | EU-GMP isolator lines at Yesan | Lotus (Taiwan), Zuellig Pharma (SE Asia) |
| Oral solid CDMO | Zyprexa tablets | Cheplapharm (Germany/Switzerland) |
| Space life-science research access | Via BRAX on future Axiom Station | Korean research and commercial users (pre-revenue) |
Pricing models are not publicly disclosed beyond reimbursement prices set by the Korean MOHW/HIRA.
Financial Narrative
All figures consolidated K-IFRS, KRW billions unless stated. Source: S&P Global Market Intelligence via StockAnalysis.com (income statement updated Aug 2026; balance sheet and cash flow FY figures). Ratios marked (c) are computed.
Margins and growth
Revenue CAGR FY2021–FY2025 (c): 12.85%. Operating income CAGR FY2021–FY2025 (c): 11.9%.
Quarterly trajectory (most recent six quarters)
Sources: Dealsite (Q1 2025, Apr 2025; Q4 2025 corrected, Feb 2026; Q2 2026, Aug 2026); SK Securities via StockHub (Q1 2026). Q2 2025 derived from Q2 2026 YoY deltas (Dealsite); Q3 2025 derived as FY2025 less other quarters (computed). H1 2026: revenue KRW 535.0bn (+8.7%), operating income KRW 44.0bn (+21.1%), gross profit KRW 199.2bn (+8.2%), OPM 8.2% — record half-year (Money Today, Aug 2026).
Balance sheet
Latest (30 Jun 2026, S&P Global via StockAnalysis): cash KRW 135.0bn, total debt KRW 388.9bn, net debt KRW 253.8bn, equity KRW 894.8bn, BVPS KRW 10,636.5 — reflecting the ~KRW 280bn Taxotere payment at closing.
Cash flow
TTM to 30 Jun 2026: OCF KRW 150.2bn, capex KRW 24.9bn, FCF KRW 125.3bn; purchase of intangibles KRW 288.1bn (Taxotere).
Ratios
TTM (Jun 2026, S&P Global): ROE 14.38%, ROA 3.19%, ROIC 5.80%, current ratio 1.71, debt/equity 0.43, debt/EBITDA 3.24, interest coverage 5.49.
Commentary on trends, inflections and drivers
Revenue. Boryung compounded revenue at ~12.9% per year from FY2021 to FY2024, driven by (i) Kanarb family line extensions; (ii) the LBA oncology brands, which lifted H1 2023 oncology sales 48% YoY; and (iii) large in-licensed/co-promoted volumes, notably K-CAB from 2024 (IBK estimated KRW 27.9bn in Q1 2024 alone). FY2025 growth stalled at 0.03% because the Q4 2025 restatement cut revenue by KRW 18.6bn to book expected price-cut clawbacks on Kanarb (Dealsite, Feb 2026); underlying FY2025 revenue before that adjustment would have been roughly 1.9% higher. Growth resumed in 2026 (H1 +8.7%), with Taxotere contributing from June.
Gross margin. The step-down from ~41% (FY2023) to ~35.7% (FY2024) coincided with the onset of large merchandise volumes (K-CAB co-promotion) that carry low margins; the mix effect, not price erosion, explains most of the change (inference from IBK 2024 data). Margin recovery began in FY2025 (36.6%) and accelerated in Q1 2026 when gross margin reached 63% on a product-revenue basis per SK Securities (different basis — StockHub summary), helped by in-house Alimta production and liquid Gemzar.
Operating income. Operating margin peaked at 7.9% in FY2023, then compressed as R&D rose 26.5% in FY2025 to KRW 65.1bn and the Kanarb provision was booked. Daily Pharm reported that, excluding the Kanarb deduction, Q4 2025 operating income would have been KRW 29.1bn rather than −KRW 0.6bn. Cumulative Kanarb-related refund provisions were reported at KRW 32.3bn (Daily Pharm, 2026). H1 2026 operating margin recovered to 8.2% even with continued provisioning and a 54.7% jump in quarterly amortisation to KRW 8.1bn after Taxotere.
Below the line. Net income is volatile because of investment revaluations (space portfolio, other securities) and FX. FY2024 benefited from a tax credit (negative tax expense of KRW 6.7bn) and FX gains; TTM June 2026 net income of KRW 120.6bn includes KRW 52.6bn FX gains and KRW 21.9bn investment gains, so the trailing P/E of 5.8x materially overstates recurring earnings power.
Balance sheet. FY2022 net debt jumped to KRW 190bn after Alimta (KRW 102.7bn intangible purchase) and working-capital build. The November 2024 KRW 175bn equity injection from the owner's vehicle restored a net-cash position, which was then redeployed: in FY2025 Boryung raised KRW 199.4bn of long-term debt ahead of the Taxotere closing, and long-term investments rose by KRW 188bn (composition not detailed in aggregated data). After closing, net debt stood at KRW 253.8bn (Jun 2026) — roughly 2.1x TTM EBITDA.
Cash flow. Working capital absorbed KRW 62bn in FY2022 and KRW 56bn in FY2023 as inventory more than doubled from FY2021 (LBA brand stock-building and in-sourcing). FY2025 was the first year of release (+KRW 29.3bn), lifting FCF to a five-year high of KRW 110.9bn. The cash conversion cycle remains long (~130 days), typical of Korean pharma with hospital receivables, but has improved from its FY2023 peak.
Returns. ROE has hovered between 7% and 9% and ROIC between 5% and 7% — below what the "1 trillion club" peers with proprietary blockbusters earn (Hanmi, Daewoong), and constrained by the space investments and equity dilution in FY2024.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Notes |
|---|---|---|
Boryung Holdings Co., Ltd. | Parent (~50.66%) | Unlisted; Jay Kim owns 51.31% after May 2026 merger (Dealsite TV, May 2026); FY2025 standalone operating loss KRW 0.26bn, net profit KRW 10.46bn (NewsSpace, 2026) |
Boryung Partners | Former shareholder (21.10%) | Absorbed into Holdings 1 May 2026 |
BRAX Space Corporation | Subsidiary (51%) | JV with Axiom Space (49%); CEO Jack (Dong-ju) Lim |
Boryung Pharma Solution | Planned 100% subsidiary | From 4 Jan 2027, subject to EGM |
Boryung Consumer Healthcare | Sister company (100% Boryung Holdings) | OTC marketing of Gelfos, Yonggaksan; CEO Seo Jung-wook (Jan 2025) |
Vigencell | Associate/affiliate | — |
Boryung Biopharma | Former affiliate | 80% sold by owner-side vehicle to Eugene PE/KDB PE consortium for ~USD 231m (KED Global, Jun 2024) |
Revenue by Segment
| Business line / franchise | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated revenue (KRW Bn) | 859.6 | 1,017.1 | 1,017.4 |
Kanarb family revenue (KRW Bn) | — | 150.9 | — |
Other: export and contract manufacturing (KRW Bn) | 75.1 | — | — |
Total exports (KRW Bn) | — | — | 12.6 |
Gelfos exports (KRW Bn) | 2.1 | 7.2 | 3.5 |
Yesan oncology injectable production value (KRW Bn) | — | 21.6 | 43.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Quarterly)
| Franchise metric (KRW Bn) | Q4 2023 | Q1 2024 | Q1 2025 | Q2 2025 | Q2 2026 |
|---|---|---|---|---|---|
Kanarb family revenue | 50.4 | 35.5 | 38.5 | 38.1 | 38.8 |
Alimta revenue | 6.4 | 6.6 | — | — | — |
Gemzar revenue | — | 4.8 | — | — | — |
Zyprexa revenue | — | 7.1 | — | — | — |
K-CAB co-promotion revenue | — | 27.9 | — | — | — |
Oncology revenue (KRW Bn)
| Oncology revenue (KRW Bn) | H1 2023 | H1 2026 |
|---|---|---|
Oncology franchise | 106.1 | 130.5 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 627.3 | 760.5 | 859.6 | 1,017.1 | 1,017.4 |
Revenue growth (%) | 11.64 | 21.23 | 13.04 | 18.32 | 0.03 |
Cost of revenue (KRW Bn) | 362.3 | 453.3 | 506.2 | 653.8 | 645.1 |
Gross profit (KRW Bn) | 264.9 | 307.2 | 353.4 | 363.4 | 372.3 |
SG&A (KRW Bn) | 171.7 | 192.4 | 214.1 | 217.1 | 216.3 |
Advertising expense (KRW Bn) | 40.5 | 44.1 | 45.4 | 47.9 | 45.2 |
R&D expense (KRW Bn) | 39.1 | 41.7 | 47.3 | 51.5 | 65.1 |
Amortisation of intangibles (KRW Bn) | 6.0 | 9.7 | 18.8 | 18.6 | 17.9 |
Operating income (KRW Bn) | 41.4 | 56.6 | 67.7 | 70.5 | 65.1 |
EBITDA (KRW Bn) | 73.5 | 94.2 | 112.1 | 113.3 | 108.6 |
Interest expense (KRW Bn) | 4.5 | 6.1 | 9.5 | 9.0 | 11.6 |
FX gain/loss (KRW Bn) | 2.4 | 10.9 | 1.0 | 19.0 | -0.2 |
Gain/loss on investments (KRW Bn) | 32.3 | -5.7 | -1.4 | -17.4 | 11.9 |
Pre-tax income (KRW Bn) | 70.7 | 58.9 | 56.3 | 63.0 | 69.8 |
Income tax (KRW Bn) | 27.6 | 16.9 | 16.1 | -6.7 | 5.5 |
Net income attributable (KRW Bn) | 43.0 | 41.9 | 40.2 | 69.6 | 64.3 |
EPS basic (KRW) | 689 | 636 | 610 | 1,020 | 766 |
EPS diluted (KRW) | 683 | 634 | 610 | 1,016 | 766 |
Dividend per share (KRW) | 100 | 100 | 100 | 100 | 160 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 42.24 | 40.39 | 41.11 | 35.73 | 36.59 |
Operating margin (%) | 6.61 | 7.44 | 7.88 | 6.93 | 6.40 |
EBITDA margin (%) | 11.72 | 12.39 | 13.04 | 11.14 | 10.67 |
Net margin (%) | 6.86 | 5.51 | 4.68 | 6.85 | 6.32 |
R&D / revenue (%) (c) | 6.24 | 5.48 | 5.50 | 5.06 | 6.40 |
Effective tax rate (%) | 39.03 | 28.76 | 28.58 | — | 7.94 |
Income Statement
| Metric (KRW Bn) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue | 240.6 | 251.5 | 280.0 | 245.3 | 255.4 | 279.6 |
Operating income | 10.9 | 25.4 | 29.4 | -0.6 | 20.2 | 23.8 |
Net income | 0.3 | 8.9 | — | 21.1 | — | 24.1 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 828.6 | 892.4 | 915.5 | 1,164.1 | 1,387.9 |
Cash and equivalents (KRW Bn) | 150.7 | 16.1 | 16.5 | 187.2 | 227.6 |
Cash and short-term investments (KRW Bn) | 201.4 | 17.9 | 20.1 | 191.8 | 254.7 |
Accounts receivable (KRW Bn) | 106.6 | 137.5 | 158.9 | 189.2 | 172.1 |
Inventory (KRW Bn) | 111.0 | 164.6 | 189.8 | 229.3 | 219.4 |
Long-term investments (KRW Bn) | 57.5 | 129.2 | 134.6 | 143.8 | 332.3 |
Goodwill and intangibles (KRW Bn) | 92.8 | 183.6 | 172.9 | 155.0 | 143.7 |
Short-term debt incl. current LTD and leases (KRW Bn) (c) | 26.3 | 113.7 | 51.6 | 42.3 | 70.9 |
Long-term debt incl. leases (KRW Bn) (c) | 189.2 | 94.6 | 152.6 | 126.3 | 259.1 |
Total debt (KRW Bn) | 215.5 | 208.3 | 204.2 | 168.6 | 330.0 |
Net debt (KRW Bn) (c) | 14.1 | 190.3 | 184.2 | -23.2 | 75.3 |
Shareholders' equity (KRW Bn) | 474.3 | 516.4 | 549.3 | 784.5 | 845.5 |
Working capital (KRW Bn) | 281.4 | 60.9 | 176.6 | 385.5 | 405.7 |
Book value per share (KRW) | 7,192 | 7,833 | 8,331 | 9,343 | 10,008 |
Cash Flow and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 60.2 | 27.8 | 42.2 | 80.6 | 133.2 |
Change in working capital (KRW Bn) | -10.1 | -62.0 | -55.9 | -43.6 | 29.3 |
Capital expenditure (KRW Bn) | 16.1 | 20.3 | 15.0 | 12.8 | 22.2 |
Free cash flow (KRW Bn) | 44.0 | 7.5 | 27.2 | 67.7 | 110.9 |
FCF margin (%) | 7.02 | 0.99 | 3.16 | 6.66 | 10.90 |
Purchase of intangibles (KRW Bn) | 43.1 | 102.7 | 8.0 | 7.2 | 7.7 |
Dividends paid (KRW Bn) | 4.5 | 6.6 | 6.6 | 6.8 | 8.4 |
Share buybacks (KRW Bn) | 4.7 | 0.2 | 0 | 0 | 0 |
Equity issued (KRW Bn) | 98.5 | 0 | 0 | 175.0 | 0 |
Net debt issued/repaid (KRW Bn) | 23.7 | -8.6 | -6.1 | -39.8 | 144.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end equity (%) (c) | 9.07 | 8.11 | 7.32 | 8.88 | 7.61 |
ROA on year-end assets (%) (c) | 5.19 | 4.69 | 4.39 | 5.98 | 4.63 |
ROIC (EBIT x 0.75 / equity + debt − cash) (%) (c) | 6.37 | 6.01 | 6.92 | 6.94 | 5.30 |
Current ratio (x) (c) | 2.80 | 1.22 | 1.88 | 2.61 | 2.59 |
Debt / equity (x) (c) | 0.45 | 0.40 | 0.37 | 0.21 | 0.39 |
Net debt / EBITDA (x) (c) | 0.19 | 2.02 | 1.64 | -0.21 | 0.69 |
Interest coverage EBIT/interest (x) (c) | 9.26 | 9.24 | 7.09 | 7.83 | 5.62 |
Asset turnover (x) (c) | 0.76 | 0.85 | 0.94 | 0.87 | 0.73 |
Days sales outstanding (c) | 62.0 | 66.0 | 67.5 | 67.9 | 61.7 |
Days inventory outstanding (c) | 111.8 | 132.6 | 136.9 | 128.0 | 124.2 |
Days payables outstanding (c) | 62.0 | 72.7 | 50.1 | 60.3 | 55.7 |
Cash conversion cycle (days) (c) | 111.8 | 125.9 | 154.3 | 135.6 | 130.2 |
Region Overview
| Region | FY2025 |
|---|---|
Domestic Korea revenue (KRW Bn) (c) | 1,004.8 |
Export revenue (KRW Bn) | 12.6 |
Export share of revenue (%) (c) | 1.24 |
Revenue by Region
| Interim exports (KRW Bn) | H1 2025 | H1 2026 |
|---|---|---|
Total exports | 3.9 | 13.1 |
Of which Taxotere | 0 | 6.8 |
Revenue by Region (Annual)
| Product / market | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Gelfos exports, mainly China (KRW Bn) | 8.0 | 9.1 | 2.1 | 7.2 | 3.5 |
Share Price & Returns
| Reference point | Price (KRW) | Source |
|---|---|---|
30 Jul 2021 (post 1.2x bonus issue) | 17,950 | Daishin Securities, Aug 2021 |
24 Aug 2023 | 9,000 | Shinhan Investment, Aug 2023 |
4 Nov 2024 allotment price | 9,670 | BioSpectator |
31 Dec 2024 close | 10,290 | Alpha Distillery |
31 Dec 2025 close | 9,010 | Alpha Distillery |
14 Oct 2026 close | 8,360 | StockAnalysis |
Performance (price only) | Value | — |
1-year (52-week) change | −0.24% (StockAnalysis, 14 Oct 2026) | — |
~3-year change (Aug 2023 → Oct 2026) | approx. −7% (computed from points above) | — |
~5-year change (Jul 2021 → Oct 2026) | approx. −53% (computed; not adjusted for dividends) | — |
YTD 2026 (31 Dec 2025 → 14 Oct 2026) | approx. −7% (computed) | — |
Beta (5Y) | 0.33 | — |
50-day / 200-day moving average | KRW 8,727 / KRW 9,059 | — |
Valuation Multiples
| Multiple | Boryung | Peer reference (Alpha Distillery median; May 2026) |
|---|---|---|
P/E trailing | 5.82 (inflated by FX/investment gains) | 9.8 |
P/E forward | 10.67 | — |
EV/EBITDA | 7.97 | — |
EV/Sales | 0.90 | — |
P/S | 0.66 | 0.74 |
P/B | 0.79 | 1.28 |
P/FCF | 5.61 | — |
Dividend yield | 1.91% | — |
Analyst Ratings & Targets
| Broker / source | Date | Rating | Target (KRW) |
|---|---|---|---|
SK Securities | 19 May 2026 | Buy | 14,000 |
Alpha Distillery (AI research site; not a broker) | 27 Jul 2026 | Buy | 11,500 |
Shinhan Investment (historical) | 25 Aug 2023 | Buy | 13,000 |
FnGuide consensus Q2 2026 | Jul 2026 | — | Revenue KRW 257.6bn, OP KRW 20.9bn (actual beat on revenue) |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (KRW) | 100 | 100 | 100 | 100 | 160 |
Dividends paid (KRW Bn) | 4.5 | 6.6 | 6.6 | 6.8 | 8.4 |
Payout ratio on EPS (%) (c) | 14.5 | 15.7 | 16.4 | 9.8 | 20.9 |
Capital Markets
| Item | Detail |
|---|---|
Moody's / S&P / Fitch | Not rated (no international ratings publicly disclosed) |
Current portion of LT debt (FY2025) | KRW 28.5bn |
Short-term borrowings (FY2025) | KRW 38.0bn |
Long-term debt (FY2025) | KRW 244.7bn |
Total debt (30 Jun 2026) | KRW 388.9bn |
Analyst Conclusions
Guidance and consensus
No formal FY2026 guidance was found. SK Securities (May 2026) cited LBA cost-of-goods improvements and Taxotere momentum in 2026–2027 behind its Buy call. Alpha Distillery models FY2026E revenue ~KRW 1,090bn and operating profit ~KRW 95bn, and FY2027E ~KRW 1,170bn / ~KRW 112bn. H1 2026 actuals (KRW 535.0bn revenue, KRW 44.0bn OP) are consistent with mid-to-high single-digit revenue growth before the full-year Taxotere effect.
Bull case
-
Taxotere is accretive and contracted: A business with EUR 70m (2024) originator sales bought for ~EUR 170m (~2.4x sales), with China anchored by a USD 277m take-or-pay contract, should lift revenue and, once produced at Yesan, gross margin.
-
Margins are inflecting: Q1 2026 OP +84.7% and H1 2026 OP +21.1% were achieved while still provisioning for Kanarb; a favourable appeal could reverse ~KRW 32bn of provisions.
-
Cheap on assets and cash flow: P/B 0.79x, P/FCF 5.6x, EV/EBITDA ~8x — below peer medians — while CDMO contracts begin contributing in 2026–2027.
Bear case
-
Kanarb erosion is structural: substance patent expired 2023; the use-patent suit was withdrawn; generics are ready; a final appeal loss means refunds plus permanently lower prices on ~16% of revenue.
-
Balance-sheet and capital-allocation risk: net debt rose to KRW 254bn post-deal; ~KRW 93bn has gone into non-earning space assets; interest coverage has halved since FY2021.
-
Minority-shareholder alignment: a discounted allotment to the owner's vehicle, a succession-driven parent merger, and a physical spin-off of the commercial arm have coincided with a ~53% share-price decline over five years.
Key catalysts and monitorables (next 12 months)
-
EGM vote on BPS (28 Oct 2026) and scale of appraisal-right exercises.
-
Q3 2026 results (est. 13 Nov 2026): first full quarter of Taxotere; Kanarb provision run-rate.
-
Seoul High Court ruling on the Kanarb price-cut appeal.
-
Ditaxel divestiture (deadline ~Dec 2026, extendable to ~Jun 2027).
-
Yesan oral-line EU-GMP/FDA cGMP/ANVISA inspections; Zyprexa CDMO exports from Q4 2026.
-
Taxotere manufacturing transfer timeline and country-by-country authorisation transfers.
-
Treasury-share use/cancellation decisions; FY2026 DPS.
-
Space-asset valuation marks (Axiom, Intuitive Machines).
Analyst verdict
Boryung is in the middle of its most consequential transformation since Kanarb's launch in 2011. The core thesis is straightforward: a domestically focused, mid-margin Korean drugmaker is converting itself into an owner-operator of originator brands with captive EU-GMP manufacturing and genuinely international revenue. The Taxotere acquisition is the proof point — it is the first time a Korean company has bought a big-pharma originator oncology business for global sale, and the Yifan contract de-risks the largest territory within four months of closing. CDMO contracts with Lotus, Cheplapharm and Zuellig show that the LBA playbook creates second-order revenue from the same plants.
Against that, the domestic earnings base is under credible pressure. Kanarb, the company's only proprietary blockbuster, faces a court-validated price cut and imminent generic competition, and management has not yet shown that Kanarb Jet and other combinations can offset that erosion in absolute terms. Reported profitability is noisy: FY2025 was restated downward, and trailing net income is flattered by FX and investment gains that should be excluded from any valuation.
Valuation reflects much of this. At roughly 0.8x book, ~8x EV/EBITDA and a double-digit FCF yield on TTM figures, the market is pricing Boryung as an ex-growth domestic generic company. If Taxotere and CDMO lift group operating margin toward 9–10% by FY2027, the shares look undervalued relative to Korean peers. The discount, however, is not purely about earnings: governance — a controlling-family chain consolidated through succession transactions, a combined chair/CEO, a minority-independent board, and sizeable space investments outside the core business — warrants a persistent discount until minority-shareholder returns improve (e.g., cancelling rather than reissuing treasury stock).
Net view: fundamentally improving, structurally under-owned, governance-discounted. The Kanarb appeal outcome and the first two full quarters of Taxotere are the decisive near-term data points.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / education | Age | Compensation |
|---|---|---|---|---|---|
Jay (Jung-kyun) Kim | Representative Director, CEO; Board Chair | Boryung CEO since Mar 2022; sole CEO since 28 Feb 2025 | Grandson of founder Kim Seung-ho, son of Kim Eun-sun; BS Industrial Engineering, University of Michigan; MS social & administrative pharmacy, Chung-Ang University; Samjong KPMG (2011); joined Boryung 2014; CEO Boryung Holdings 2019 | Born 1985 (41) | — |
Kim Sung-jin | Chief Strategy Officer; Inside Director | Inside director since Mar 2022; re-elected Mar 2025 | Former head of Global Investment Center; led Taxotere, CDMO, strategy | — | FY2025 total KRW 4,064.75m, incl. 400,000 restricted shares valued at KRW 3,460m (Daily Pharm, Sept 2026) |
Park Yoon-sik | Vice President | — | — | — | Received RSA in 2025 (amount not disclosed) |
Jack (Dong-ju) Lim | Head, New Portfolio Investment Group; CEO, BRAX Space | Joined 2021 | Oversaw Axiom Space investment | — | — |
Chang Doo-hyun | Former co-CEO (pharma operations) | 2022 – resigned 28 Feb 2025 | Professional manager | — | — |
“—” = not publicly disclosed.
Governance Overview
| Item | Detail |
|---|---|
Composition | 4 executive directors and 2 independent directors (company governance page, data as of c.2022) |
Chair | Jay Kim (CEO) — chair and CEO roles combined since 2022 |
Committees | Not publicly disclosed in sources reviewed; ESG performance reported regularly to the board; a Chief Risk Officer function exists (KCGS/press summaries, Nov 2025) |
Independence assessment | Minority independent board (2 of 6), combined chair/CEO, controlling owner — weak by international standards |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Boryung Holdings Co., Ltd. | ~50.66% (18,097,207 shares transferred from Boryung Partners added to prior 29.71%) | Dealsite TV, May 2026 |
Boryung Holdings and related parties (10 persons) | 64.78% | Alpha Distillery |
Boryung Jungbo Foundation | 0.7% (471,670 shares) | Company governance page (older data) |
Treasury shares | ~1.6m shares (approx., after 1m cancellation and partial 2026 purchases) | — |
Foreign investors | ~4.89% | Alpha Distillery |
Insiders (S&P definition) | 10.15% | StockAnalysis/S&P Global |
Institutions | 7.10% | StockAnalysis/S&P Global |
Free float | ~28.3m shares | StockAnalysis/S&P Global |
Competitive Landscape
Competitors by Segment
| Area | Competitors |
|---|---|
Korean ETC (broad) | Yuhan, GC Biopharma, Chong Kun Dang, Daewoong Pharmaceutical, Hanmi Pharmaceutical, HK inno.N, JW Pharmaceutical, Dong-A ST, Ildong, Daewon, Kwangdong (scale peer) |
ARB hypertension / Kanarb generics | Dongkook (Pimamono), Daewoong Bio (Kanaden), Alliko (Alkana), Korea Hutex (Hunab); originator ARBs from multinationals; Hanmi Amosartan family, Chong Kun Dang Telmi series |
Docetaxel / cytotoxics in Korea | Generic docetaxel suppliers (post-divestiture owner of Ditaxel); other cytotoxic generic makers |
Taxotere global markets | Local docetaxel generic producers in China, EU, LatAm |
Legacy brand consolidation (global) | Cheplapharm (also a partner), other originator-brand acquirers |
CDMO (cytotoxic/oral) | Korean and Asian CDMOs (not individually verified) |
Peer Comparison FY2025
| Company | Revenue FY2025 | Operating profit FY2025 | Operating margin (%) |
|---|---|---|---|
Yuhan | 2,186.6 | 104.4 | 4.8 |
GC Biopharma | 1,991.3 | 69.1 | 3.5 |
Chong Kun Dang | 1,692.4 | 80.6 | 4.8 |
Kwangdong | 1,659.5 | 31.0 | 1.9 |
Daewoong Pharmaceutical | 1,570.9 | 196.8 | 12.5 |
Hanmi Pharmaceutical | 1,547.5 | 257.8 | 16.7 |
HK inno.N | 1,063.2 | 110.9 | 10.4 |
Boryung | 1,017.4 | 65.1 | 6.4 |
Peer Comparison FY2025 — Revenue FY2025
| Metric | Boryung | Hanmi | Daewoong | HK inno.N |
|---|---|---|---|---|
Revenue FY2025 (KRW Bn) | 1,017.4 | 1,547.5 | 1,570.9 | 1,063.2 |
Revenue growth FY2025 (%) | 0.03 | — | — | — |
Operating margin FY2025 (%) | 6.4 | 16.7 | 12.5 | 10.4 |
R&D intensity (%) | 6.4 | — | — | — |
Key proprietary franchise | Kanarb (off-patent) | Rosuzet/Amosartan family | Fexuclue/Envlo | K-CAB (P-CAB) |
“—” = not publicly disclosed.



